Τελευταία ενημέρωση :
26/03/2024
φάρμακο κατά του καρκίνου   Cisplatin  
Ενέσιμο
Σταθερότητα διαλυμάτων Σταθερότητα σε μίγματα Παράγοντας που επηρεάζει τη σταθερότητα Συμβατότητες Τρόπος χορήγησης Βιβλιογραφία Pdf
   χημική δομή  

Εμπορική ονομασία   Εμπορική ονομασία     

Οι εμπορικές ονομασίες είναι ενδεικτικές και η σύνθεση των εκδόχων μπορεί να διαφέρει ανάλογα με τη χώρα και τα εργαστήρια

Abiplatin Νότιος Αφρική
Accocit Μεξικό
Briplatin Ιαπωνία
Cisplatex Βραζιλία
Cisplatin Αυστραλία, Αυστρία, Βέλγιο, Καναδάς, Σαουδική Αραβία
Cisplatina Βραζιλία
Cisplatine Βέλγιο, Γαλλία
Cisplatyl Γαλλία, Ελλάδα, Σαουδική Αραβία, Τουρκία
Citoplatino Αργεντινή, Ιταλία
Citoplax Βραζιλία
Corsis Μεξικό
Insel Βραζιλία
Neoplatin Ισπανία
Pamifect Ινδία
Placis Ισπανία, Τουρκία
Platamine Ελλάδα, Ιταλία, Μαρόκο, Τυνησία
Platanovag Αργεντινή
Platiblastin Αυστρία
Platidiam Ουγγαρία, Πολωνία
Platinex Γερμανία, Ιταλία, Μεγάλη Βρετανία
Platinol Αυστρία, Βέλγιο, Δανία, Ελβετία, Ελλάδα, Η.Π.Α., Λουξεμβούργο, Μεξικό, Ολλανδία, Σουηδία, Φινλανδία
Platistil Ισπανία
Platistine Βέλγιο, Βραζιλία, Λουξεμβούργο
Platosin Αίγυπτος, Βέλγιο, Βενεζουέλα, Ελλάδα, Ιαπωνία, Ολλανδία, Ρουμανία, Τουρκία
Pronto Platamine Ιταλία
Zuridry Μεξικό
Βιβλιογραφία   Ενέσιμο   Βιβλιογραφία : Cisplatin  
τύπος δημοσίευση
3 εφημερίδα Trissel LA, Martinez JF.
Compatibility of amifostine with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1995 ; 52: 2208-2212.
53 εφημερίδα Henry DW, Marshall JL, Nazzar OD, Fox JL, Leff RD.
Stability of cisplatin and ondansetron hydrochloride in admixtures for continuous infusion.
Am J Health-Syst Pharm 1995 ; 52: 2570-2573.
57 εφημερίδα Mayron D, Gennaro AR.
Stability and compatibility of granisetron hydrochloride in IV solutions and oral liquids and during simulated Y-site injection with selected drugs.
Am J Health-Syst Pharm 1996 ; 53: 294-304.
81 εφημερίδα Trissel LA, Martinez JF.
Compatibility of piperacillin sodium plus tazobactam with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1994 ; 51: 672-678.
84 εφημερίδα Trissel LA, Martinez JF.
Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1994 ; 51: 495-499.
85 εφημερίδα Trissel LA, Bready BB.
Turbidimetric assessment of the compatibility of taxol with selected other drugs during simulated Y-site injection.
Am J Hosp Pharm 1992 ; 49: 1716-1719.
91 εφημερίδα Lober CA, Dollard PA.
Visual compatibility of gallium nitrate with selected drugs during Y-site injection.
Am J Hosp Pharm 1993 ; 50: 1208-1210.
99 εφημερίδα Trissel LA, Martinez JF.
Compatibility of aztreonam with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1995 ; 52: 1086-1090.
147 εφημερίδα Pujol Cubells M, Prat Aixela J, Girona Brumos V, Duran Pou S, Villaronga Flaque MV.
Stability of cisplatin in sodium chloride 0.9% intravenous solution related to the container’s material.
Pharm World Sci 1993 ; 15: 34-36.
149 εφημερίδα Rochard E, Barthes D, Courtois P.
Stability of cisplatin in ethylene vinylacetate portable infusion-pump reservoirs.
J Clin Pharm Ther 1992 ; 17: 315-318.
164 εφημερίδα Benaji B, Dine T, Luyckx M, Brunet C, Goudaliez F, Mallevais ML, Cazin M, Gressier B, Cazin JC.
Stability and compatibility of cisplatin and carboplatin with PVC infusion bags.
J Clin Pharm Ther 1994 ; 19: 95-100.
169 εφημερίδα Trissel LA, Martinez JF.
Physical compatibility of melphalan with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1993 ; 50: 2359-2363.
244 εφημερίδα Trissel LA, Martinez JF.
Compatibility of filgrastim with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1994 ; 51: 1907-1913.
249 εφημερίδα Trissel LA, Martinez JF.
Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1996 ; 53: 1041-1045.
251 εφημερίδα Trissel LA, Gilbert DL, Martinez JF.
Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 2708-2713.
300 εφημερίδα Trissel LA, Gilbert DL, Martinez JF.
Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 1287-1292.
301 εφημερίδα Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM.
Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 1295-1300.
307 εφημερίδα Trissel LA, Martinez JF.
Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1994 ; 51: 1792-1799.
331 εφημερίδα Marquardt ED.
Visual compatibility of hydroxyzine hydrochloride with various antineoplasic agents.
Am J Hosp Pharm 1988 ; 45: 2127.
334 εφημερίδα Trissel LA, Tramonte SM, Grilley BJ.
Visual compatibility of ondansetron hydrochloride with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1991 ; 48: 988-992.
335 εφημερίδα Trissel LA, Bready BB, Kwan JW, Santiago NM.
Visual compatibility of sargramostim with selected antineoplasic agents, anti-infectives, or other drugs during simulated Y-site injection.
Am J Hosp Pharm 1992 ; 49: 402-406.
409 εφημερίδα Cheung YW, Cradock JC, Vishnuvajjala BR, Flora KP.
Stability of cisplatin, iproplatin, carboplatin, and tetraplatin in commonly used intravenous solutions.
Am J Hosp Pharm 1987 ; 44: 124-130.
410 εφημερίδα Zieske PA, Koberda M, Hines JL, Knight CC, Sriram R, Raghavan NV, Rabinow BE.
Characterization of cisplatin degradation as affected by pH and light.
Am J Hosp Pharm 1991 ; 48: 1500-1506.
413 εφημερίδα Stewart CF, Fleming RA.
Compatibility of cisplatin and fluorouracil in 0.9% sodium chloride injection.
Am J Hosp Pharm 1990 ; 47: 1373-1377.
417 εφημερίδα Stewart CF, Hampton EM.
Stability of cisplatin and etoposide in intravenous admixtures.
Am J Hosp Pharm 1989 ; 46: 1400-1404.
492 εφημερίδα Trissel LA, Parks NPT, Santiago NM.
Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1991 ; 48: 2186-2189.
660 εφημερίδα Michaels MR, Stauffer GL, Haas DP.
Propofol compatibility with other intravenous drug products - Two new methods of evaluating IV emulsion compatibility.
Ann Pharmacotherapy 1996 ; 30: 228-232.
742 εφημερίδα Greene RF, Chatterji DC, Hiranaka PK, Gallelli JF.
Stability of cisplatin in aqueous solution.
Am J Hosp Pharm 1979 ; 36: 38-43.
855 εφημερίδα Hrubisko M, Mc Gown AT, Prendiville JA, Radford JA, Thatcher N, Fox BW.
Suitability of cisplatin solutions for 14-day continuous infusion by ambulatory pump.
Cancer Chemother Pharmacol 1992 ; 29: 252-255.
872 εφημερίδα Zhang YP, Xu QA, Trissel LA, Gilbert DL, Martinez F.
Compatibility and stability of paclitaxel combined with cisplatin and with carboplatin in infusion solutions.
Ann Pharmacotherapy 1997 ; 31: 1465-1470.
905 εφημερίδα Trissel LA, Martinez JF.
Screening teniposide for Y-site physical incompatibilities.
Hosp Pharm 1994 ; 29: 1010-1017.
921 εφημερίδα Trissel LA, Gilbert DL, Martinez JF.
Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration.
Hosp Pharm 1998 ; 33: 284-292.
1026 εφημερίδα Mayron D, Gennaro AR.
Stability and compatibility of topotecan hydrochloride with selected drugs.
Am J Health-Syst Pharm 1999 ; 56: 875-881.
1080 εφημερίδα La Folette JM, Arbus MH, Lauper RD.
Stability of cisplatin admixtures in polyvinyl chloride bags.
Am J Hosp Pharm 1985 ; 42: 2652.
1410 εφημερίδα Trissel LA, Martinez JF, Simmons M.
Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection.
J Am Pharm Assoc 1999 ; 39: 141-145.
1415 εφημερίδα Trissel L.A, Gilbert D.L, Martinez J.F, Baker M.B, Walter W.V, Mirtallo J.M.
Compatibility of medications with 3-in-1 parenteral nutrition admixtures.
JPEN 1999 ; 23: 67-74.
1423 εφημερίδα Trissel LA, Martinez JF, Gilbert DL.
Compatibility of gemcitabine hyrochloride with 107 selected drugs during simulated Y-site injection.
J Am Pharm Assoc 1999 ; 39: 514-518.
1496 εφημερίδα Trissel LA, Martinez JF, Gilbert DL.
Screening cladribine for Y-site physical compatibility with selected drugs.
Hosp Pharm 1996 ; 31: 1425-1428.
1625 εφημερίδα Trissel LA, Saenz C, Williams YW, Ingram D.
Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration.
Int J Pharm Compound 2001 ; 5: 314-321.
1729 εφημερίδα Mittner A, Vincze Z, Jemnitz K.
Stability of cisplatin containing infusion.
Pharmazie 1998 ; 53: 490-492.
1925 εφημερίδα Trissel LA , Williams KY, Gilbert DL.
Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions.
J Am Pharm Assoc 2000 ; 40: 515-519.
1950 εφημερίδα Trissel LA, Yanping Z.
Physical and chemical stability of palonosetron HCl with cisplatin, carboplatin and oxaliplatin during simulated Y-site administration.
J Oncol Pharm Practice 2004 ; 10: 191-195.
1953 εφημερίδα Trissel LA, Saenz CA, Ogundele AB, Ingram DS.
Physical compatibility of pemetrexed disodium with other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2004 ; 61: 2289-2293.
1982 εφημερίδα Trissel LA, Ogundele AB.
Compatibility of anidulafungin with other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2005 ; 62: 834-837.
2247 εφημερίδα Chan P, Heatherly K, Kupiec T.C, Trissel L.A.
Compatibility of caspofungin acetate injection with other drugs during simulated Y-site coadministration.
Int J Pharm Compound 2008 ; 12, 3: 276-278.
2262 εφημερίδα Brammer MK, Chan P, Heatherly K, Trusley C, Kupiec TC, Trissel LA, Psathas PA, Gilmor T, Schaufelberger D.
Compatibility of doripenem with other drugs during simulated Y-site administratioN
Am J Health-Syst Pharm 2008 ; 65: 1261-1265.
3183 εφημερίδα Sewell G
Physical and chemical stability of cisplatin infusions in PVC containers.
EJOP 2010 ; 4, 3: 11-13.
3474 Εργαστήριο Fluorouracil - Summary of Product Characteristics
Accord Healthcare Limited 2009
3574 Εργαστήριο Ondansetron - Résumé des caractéristiques du produit
Accord Healthcare France SAS 2013
3578 Εργαστήριο Cisplatin - Summary of Product Characteristics
Accord Healthcare 2011
3602 Εργαστήριο Mesna (Uromitexan®)- Summary of Product Characteristics
Baxter SAS 2013
3670 εφημερίδα Sewell G, Massimini M.
Studies on the stability and compatibility of cytotoxic drug infusion with the Tevadaptor system.
EJOP 2014 ; 8, 3: 26-30.
4084 Εργαστήριο Cisplatine - Résumé des caractéristiques du produits
Accord Health Care 2017
4137 εφημερίδα Patel T, Sewell G.
Short Report : Extended Stability Studies on Bortezomib Injection and Infusions of Cisplatin and Pemetrexed (all Accord Healthcare).
Newsletter Stabilis 2018 41;2-6
4589 Εργαστήριο Pemetrexed Mylan - Résumé des caractéristiques du produit
Mylan 2021

  Mentions Légales